The APBB2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population disrupting the APBB2 gene in the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model enables examination of the adaptor protein APBB2 (Fe65-like protein 1) in signal transduction, transcriptional regulation, and cell migration. The polyclonal nature reflects pooled gene disruptions without single-cell cloning, offering a heterogeneous knockout background suitable for population-level genetic studies.
The A-549 cell line, derived from human alveolar basal epithelial adenocarcinoma, is a established model for lung adenocarcinoma research. These adherent cells retain epithelial characteristics, express wild-type p53, and are tumorigenic in xenografts. Widely used to study cancer cell biology, they prove ideal for investigating epithelial-to-mesenchymal transition, migration, invasion, and drug responses. The well-characterized signaling landscape of A-549 cells supports targeted gene knockout studies addressing both cancer and neurodegenerative pathways.
APBB2 operates as a scaffold adaptor binding the APP intracellular domain (AICD) released by ??-secretase cleavage. In complex with Tip60/KAT5 and CP2/TFCP2, APBB2 regulates transcription of targets including BACE1, GSK-3??, and p53. These interactions couple APP processing to Notch and p53 signaling, modulating genes for cell adhesion, apoptosis, and migration. Phosphorylation by CDK5 and GSK-3 regulates APBB2 function. Through these mechanisms, APBB2 integrates extracellular cues with transcriptional outcomes vital for cellular homeostasis and disease.
In A-549 cells, which express functional p53, APBB2 knockout enables dissection of p53-dependent transcriptional programs and apoptotic responses. Given the highly migratory nature of this line, the model is especially valuable for probing APBB2’s role in cell migration and invasion, processes central to metastasis. The convergence of APP-related signaling with cancer pathways in these cells also offers a unique platform to investigate molecular links between Alzheimer??s disease pathology and lung adenocarcinoma progression.
Typical applications include Western blotting to verify APBB2 loss and assess downstream effectors, RT-qPCR for gene expression profiling, and APP processing assays using ELISA or immunoblotting for AICD. Functional assays such as Transwell migration/invasion, immunofluorescence for nuclear translocation, and ChIP-qPCR to examine promoter binding provide mechanistic insight. Apoptosis can be evaluated by Annexin V staining. For inquiries or custom experimental support, please contact Ascent Research.
